MySugr which has emerged from Austria and is a very popular digital platform for Diabetes Management. It has now been acquired by one of the health giants called “Roche”. At the Roche’s Diabetes Care it has become the heart of the patient-centered Digital Health Services.The plans of the Roche are to keep this acquisition an open and independent platform. From this platform the health insurance and medical technology companies would be able to take benefit along with the pharmaceutical companies.

How MySugr Works?

The MySugr App is like a diary for the diabetic patients. It helps them track their blood sugar level along with the activities, medications and all of this works in cooperation with the insurers. Previously, since 2014 it has been working with Roche and has also got funding from the Roche’s Venture Fund.

The Acquisition Price:

Although the amount of the sale wasn’t revealed in public, but it could possibly have been the biggest health care exits in Europe up till now. As well as, it would have been a significant exit from the Austrian Startup Scene. However, some of the observers had said that "MySugr valued between $75 Million and $100 Million". While we look around at its competitors Livongo raised $70 Million and another one called Glooko has been able to raise $35 Million.

About MySugr:

In 2012, Fredrik Debong, Gerald Stangl, Micheal Forisch and Frank Westermann founded MySugr. It is considered to be the market leader right now as it serves one million users from around the world. At the moment is available in 52 countries and in 13 languages, however it could expand in countries-wise as well as in languages-wise.

The CEO Frank Westermann:

The CEO of the MySugr App, who is also its co-founder says: “Thanks to the expertise and the global network of Roche, MySugr will become an indispensable companion for an easier life with diabetes,”